Financial Result for the Quarter ended June 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kabra Drugs Ltd reported its first-ever revenue from operations of Rs. 715 lakhs for Q1 FY26 (quarter ended June 30, 2025), compared to nil revenue in the same quarter last year and the full FY25. Other income was minimal at Rs. 1.62 lakhs, taking total income to Rs. 716.62 lakhs. Total expenses stood at Rs. 766.60 lakhs, driven by purchases of stock-in-trade (Rs. 675 lakhs), employee costs (Rs. 37.81 lakhs), and other expenses (Rs. 53.46 lakhs). The company posted a net loss of Rs. 49.98 lakhs, though this was an improvement over the Rs. 54.57 lakh loss in Q1 FY25. Loss per share stood at Rs. 0.21. The statutory auditor (PPN And Company) issued an unmodified limited review report with no qualifications or emphasis of matter.
The first reported operating revenue is a positive structural development, but the company remains loss-making with expenses still exceeding income. Shareholders should watch whether the new revenue stream scales sustainably in coming quarters, as the stock could see volatility given the small size of operations relative to the share capital base (Rs. 2,370.79 lakhs).